ReviewChem & bio engineering2026
New Frontiers in AI-Nano Converged Platforms for Intelligent Diagnostics, Therapeutics, and Safety Evaluation.
Review in Chem & bio engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The complexity of nanomedicine poses a significant challenge to traditional empirical methods. Machine learning (ML), with its ability to parse high-dimensional data and predict nonlinear interactions, is empowering AI nano fusion platforms, driving innovation in diagnostic and therapeutic evaluation paradigms. This review explores breakthrough applications of ML in core areas of nanomedicine, including intelligent diagnosis (such as ML enhanced nanosensors for high-precision noninvasive cancer early screening), precision therapy (such as closed-loop system driven rational design and delivery optimization of nanomedicine), safety assessment (such as interpretable AI prediction of biological and environmental toxicity of nanomaterials), and clinical translation (to address scientific challenges related to standardization, reproducibility, and regulatory). The paper provides an in-depth analysis of the key bottlenecks currently facing the transition from laboratory to clinical application, such as batch differences, dynamic interference, and regulatory lag. Based on recent research progress, a future path to achieve an intelligent closed-loop of "design diagnosis and treatment evaluation" is proposed, providing key insights for the development of the next generation of safe and efficient intelligent nanodiagnosis and treatment platforms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.